Novorapid Flexpen

Novorapid Flexpen

Description:

Novorapid Flexpen (NOVORAPID 100 i.u./ml 5 Flexpen) is a rapid‑acting insulin analog injection containing insulin aspart, used for the treatment and control of diabetes mellitus in adults, adolescents, and children. It is a prescription antidiabetic medicine designed to provide fast onset blood glucose–lowering action around meal times. Each prefilled Flexpen delivers insulin aspart at a concentration of 100 i.u./ml, allowing accurate dose adjustment and convenient subcutaneous self‑administration as part of an overall diabetes management plan that includes diet, exercise, and regular blood glucose monitoring.

Indications:

• Management of diabetes mellitus in adults, adolescents, and children who require insulin for the control of blood glucose.
• Type 1 diabetes mellitus (insulin‑dependent diabetes) for basal–bolus or multiple daily injection regimens, typically as the prandial (meal‑time) insulin.
• Type 2 diabetes mellitus when oral antidiabetic medicines alone are insufficient to achieve adequate glycemic control, or when insulin therapy is clinically indicated.
• Control of postprandial (after‑meal) hyperglycemia by providing rapid onset glucose‑lowering effect.
• Use in combination with intermediate‑acting or long‑acting insulin preparations or other antidiabetic agents as prescribed by a healthcare professional.

Active Ingredients / Key Components:

• Insulin aspart – 100 i.u./ml (rapid‑acting insulin analog)
• Other excipients (such as glycerol, phenol, metacresol, zinc chloride, disodium phosphate dihydrate, sodium chloride, hydrochloric acid/sodium hydroxide for pH adjustment, and water for injections) are commonly present in insulin aspart solutions; however, the exact full excipient list for this specific product presentation is not available in the provided information.

Dosage & Administration / How to Use:

• Novorapid Flexpen is for subcutaneous injection only and must be used exactly as prescribed by your doctor or diabetes specialist.
• Typical timing: Inject immediately before a meal. Your doctor may advise injecting shortly after starting a meal in specific situations. Always follow medical advice.
• Dosage: The dose is individualized based on blood glucose measurements, type of diabetes, body weight, diet, physical activity, and concomitant medications. There is no standard universal dose; your healthcare provider will determine your units per injection and total daily requirement.
• Administration sites: Inject into the subcutaneous tissue of the abdomen, thigh, upper arm, or buttock. Rotate injection sites within the same area to reduce the risk of lipodystrophy (changes in fat tissue).
• Do not inject into a vein or muscle unless specifically instructed by a healthcare professional.
• Using the Flexpen:
  • Check the label to ensure you are using Novorapid 100 i.u./ml.
  • Inspect the solution: it should be clear, colorless, and free from particles. Do not use if cloudy, colored, or if particles are visible.
  • Attach a new sterile needle before each injection.
  • Prime the pen according to the manufacturer’s instructions (usually by dialing a small dose and expelling it) to ensure insulin flow.
  • Dial the prescribed dose in units using the dose selector.
  • Inject subcutaneously as demonstrated by your healthcare provider, then keep the needle under the skin for several seconds to ensure full dose delivery.
  • Remove and safely discard the needle after each injection. Do not share your Flexpen or needles with anyone.
• Use in combination therapy: When used with intermediate‑ or long‑acting insulin or oral antidiabetics, follow your doctor’s schedule for each medicine.
• If you miss a dose or inject too little, monitor your blood glucose and follow your doctor’s instructions for correction doses. Do not double dose without medical advice.

Clinical Benefits:

• Provides rapid onset blood glucose control around meal times, helping to reduce postprandial spikes in blood sugar.
• Supports effective long‑term management of both type 1 and type 2 diabetes when used as part of a comprehensive treatment plan.
• Flexible dosing with a prefilled pen device enables accurate unit‑by‑unit dose adjustment tailored to individual needs.
• Convenient, portable Flexpen design improves treatment adherence and facilitates insulin use at home, work, or while traveling.
• Helps reduce the risk of diabetes‑related complications associated with poor glycemic control, such as neuropathy, nephropathy, and retinopathy, when used consistently as prescribed.

Warnings & Contraindications:

• Do not use Novorapid Flexpen if you are allergic (hypersensitive) to insulin aspart or any of the excipients in the formulation.
• Do not use if the insulin solution is cloudy, colored, or contains visible particles, or if the pen is damaged.
• Hypoglycemia (low blood sugar) is the most common and potentially serious side effect of insulin therapy. Learn to recognize symptoms and always carry a fast‑acting carbohydrate source (such as glucose tablets or sugary drink).
• Use with caution in patients with renal or hepatic impairment; insulin dose adjustments may be required under medical supervision.
• Changes in insulin type, strength, manufacturer, or dosing regimen must be done only under close medical supervision, as they may require dose adjustments.
• Alcohol consumption may enhance or reduce the blood‑glucose‑lowering effect of insulin; discuss safe limits with your doctor.
• Beta‑blockers and some other medicines may mask the symptoms of hypoglycemia. Inform your doctor about all medications and supplements you are taking.
• Consult your doctor before use if pregnant, planning pregnancy, or breastfeeding. Insulin requirements may change during pregnancy and after delivery.
• Use with caution in patients with hypoglycemia unawareness or recurrent episodes of low blood sugar.
• Not intended to diagnose, treat, cure, or prevent any disease on its own; it is a prescription medicine used as part of a comprehensive diabetes management plan.
• Keep out of reach of children.

Side Effects:

• Very common: Hypoglycemia (low blood sugar), with symptoms such as sweating, shakiness, palpitations, hunger, headache, dizziness, confusion, blurred vision, or difficulty concentrating. Severe hypoglycemia can lead to loss of consciousness or seizures and requires urgent medical attention.
• Common: Injection site reactions including redness, pain, itching, swelling, or bruising at the injection area. These are usually mild and transient.
• Less common: Lipodystrophy (thickening or thinning of the fatty tissue) at injection sites, particularly if the same site is used repeatedly.
• Rare: Generalized allergic reactions such as rash, itching, shortness of breath, rapid heartbeat, or swelling of the face, tongue, or throat (angioedema). Seek immediate medical attention if signs of severe allergy occur.
• Fluid retention and edema may occur, especially when improving previously poor glycemic control.
• Contact your doctor promptly if you experience persistent or severe side effects, or if your blood glucose remains uncontrolled.

Storage Instructions:

Store unopened Novorapid Flexpen in a refrigerator at 2–8°c. Do not freeze and do not place near the freezer compartment or cooling element. Protect from direct heat and light. Once in use, the Flexpen may typically be kept at room temperature below the maximum temperature specified in the package leaflet (exact temperature and in‑use duration , please check the product leaflet or the manufacturer’s official website; follow the official product leaflet or pharmacist’s advice). Keep the pen cap on when not in use. Do not use after the expiry date printed on the pack. Keep container out of the sight and reach of children.

Specifications:

• Active ingredient: Insulin aspart 100 i.u./ml.
• Product form: Prefilled insulin injection pen for subcutaneous use.
• Pack size: 5 Flexpen prefilled insulin pens (exact ml volume per pen is not specified in the provided information).
• Intended users: Adults, adolescents, and children with diabetes mellitus requiring insulin therapy, as prescribed by a healthcare professional.
• Route of administration: Subcutaneous injection.

Disclaimer:
All pharmacy products are intended for general use only and do not replace professional medical advice, diagnosis, or treatment. Always consult a healthcare provider before use. Results may vary, and no specific outcomes are guaranteed. Products are not intended to diagnose, treat, cure, or prevent any disease unless stated. Follow label instructions carefully, as misuse may cause adverse effects. Compliance with local laws is the customer’s responsibility.